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recovery; post-event health states represented chronic impact. UK general popula-
tion respondents valued the health states in time trade-off tasks with time horizons 
of one year for acute states and ten years for chronic states. Results: A total of 200 
participants completed interviews (55% female; mean age = 46.6y). Among acute 
health states, stroke had the lowest utility (0.33), followed by heart failure (0.60) and 
ACS (0.67). Utility scores for chronic health states followed the same pattern: stroke 
(0.52), heart failure (0.57), and ACS (0.82). For stroke and ACS, acute utilities were 
significantly lower than utilities for chronic post-event (difference = 0.20 and 0.15, 
respectively; both p < 0.0001). ConClusions: Results add to previously published 
utilities for cardiovascular events by distinguishing between chronic post-event 
health states and acute health states that include the event and its immediate 
impact. Findings suggest that acute and chronic impact should be considered when 
selecting scores for use in cost-utility models. Thus, the current utilities provide a 
unique option that may be used to represent the acute and chronic impact of car-
diovascular conditions in economic models comparing treatments that may delay 
or prevent the onset of cardiovascular events.
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objeCtives: We aimed to understand the short-term impact on quality of life 
associated with Non VKA Oral AntiCoagulants (NOACs) use in patients with AF. We 
obtained baseline (BL) and follow-up (FU) data on the health state of AF patients 
under everyday practice conditions in the PREvention oF thromboembolic events 
– European Registry in Atrial Fibrillation (PREFER in AF). Methods: PREFER in AF 
documents AF patients in terms of clinical characteristics, management, qual-
ity of life and other outcome parameters. The EuroQol EQ-5D-5L descriptive sys-
tem and visual analogue scale (VAS) were applied in PREFER in AF at BL and FU 
to obtain patient-reported generic health-related quality of life information and 
utility weights. Results: Of the 6390 AF patients at follow-up 1895 (29.7%) had 
paroxysmal, 1533 (24.0%) persistent, 474 (7.4%) long-standing persistent, and 2488 
(38.9%) permanent AF. Comorbidities were highly prevalent. 3344 AF patients (61.1% 
males, mean age 71.7 ± 9.85 years) provided EQ-5D-5L data both at BL and 12-month 
FU. On the VAS (range 0-100), the mean score at FU was 68.8 ±18.1 points, with 
no major differences between patients on NOACs (68.3), VKAs (68.9), AP (70.1), or 
VKA+AP (71.7), respectively. All scores improved from baseline from 0.36 in patients 
on VKA to 1.77 for those on AP. The overall utility index at FU was 0.80 ±0.21. At FU 
the 409 patients on NOACs had a utility score of 0.79 (change from BL, -0.01), the 
1789 patients VKAs 0.80 (-0.01), the 237 patients on AP 0.81 (+0.01), the 151 patients 
on VKA and AP 0.80 (-0.01) and the 749 patients receiving neither VKAs nor AP 
0.80 (0.00). ConClusions: Patients with AF present with reduced self-reported 
quality of life compared to the general population. Patients receiving NOACs had 
similar quality of life both at baseline and after 12-month FU, when compared to 
alternative medications.
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objeCtives: Non-VKA oral anticoagulants (NOAC), which do not need routine 
monitoring, have the potential to improve the quality of life (QoL) in patients on 
long-term treatment for venous thromboembolism (VTE). We aimed to obtain 
contemporary data on the health state of patients with VTE under daily practice 
conditions. Methods: PREFER in VTE is a non-interventional study in 7 countries 
(France, Germany, Austria, Switzerland, Italy, Spain, UK) that prospectively docu-
ments patients after an event of acute deep venous thrombosis (DVT) or pulmo-
nary embolism (PE) in terms of clinical characteristics, management, quality of life 
and other outcome parameters. The EuroQol EQ-5D-5L consists of the 5-dimension 
descriptive system used to derive utility scores and the visual analogue scale (VAS), 
measuring self-rated health (scale 0-100). Results: A total of 2790 patients with 
acute VTE at baseline (BL: 1640 DVT, 1150 PE ±DVT) and 723 patients at an interim 
analysis at 6 months (443 DVT and 280 PE ±DVT) completed the EQ-5D-5L. On the 
EQ VAS for current health state, the mean score at 6 months was 73.8 points (change 
from BL +10.9), with similar values in DVT patients (74.6, change from BL +9.8) 
compared to PE patients (72.4, change from BL +12.4). Between BL and 6-month 
follow-up, index values increased in all medication classes (heparin only: 0.66 to 
0.75; heparin/VKA: 0.70 to 0.84; NOAC: 0.73 to 0.87). Overall the index value increased 
from 0.69 to 0.83 (DVT: 0.71 to 0.85, PE: 0.67 to 0.81). ConClusions: Under clinical 
practice conditions, patients on NOAC and heparin/VKA had larger increases in their 
health state scores than those on heparin only. This generic QoL tool detected only 
small differences between treatment options. Six months after the event, patients 
with DVT had similar self-reported QoL on the VAS compared to patients with PE, 
and patients with DVT had somewhat higher utility values.
questions that presented a pair of virtual patients who were prescribed different 
treatments defined by: reduction in the risks of nonfatal MI and fatal MI, treat-
ment-related risk of serious infection, mode and frequency of administration, and 
monthly medication cost. Half of the choice questions asked respondents to select 
the treatment to which they would most likely be nonadherent. The other half asked 
respondents to state which of two virtual patients was better off after learning how 
adherent each was to each medication. Limited dependent-variable models were 
used to estimate weights indicating the impact of treatment and respondent char-
acteristics on stated-adherence and quantifying the stated impact of nonadherence 
on respondents’ well-being. Results: Results indicated that reductions in the risk 
of a nonfatal MI had the largest effect on stated adherence, followed by medication 
cost, the risk of serious infection, and lastly mode and frequency of administration. 
Results also show that reductions in compliance had a significant impact on the 
perceived overall benefits of prophylactic treatments. ConClusions: We find that 
both clinical and nonclinical factors can impact treatment adherence, suggesting 
that the flexibility to include a variety of factors with SP models can be useful in 
understanding patient compliance.
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objeCtives: The aim of the study was to assessment of compliance by adolescents 
in the field of pharmacological and non-pharmacological methods of hyperten-
sion treatment. Methods: The study included 62 patients (20 women, 42 men) 
diagnosed with hypertension and treated in specialist health care facilities. As 
a research tool was used questionnaire prepared on the basis of recent litera-
ture. Results: The vast majority of respondents (72,7%) declared that regularly taking 
antihypertensive drugs. The proportion of patients regularly taking antihypertensive 
drugs was higher in patients treated with monotherapy than polytherapy (48,5% vs 
24,2%). Among the methods of non-pharmacological treatment of hypertension the 
most accepted lifestyle change in the study population was smoking cessation (83,8% 
of respondents) and reduction of salt consumption (64,5% of respondents), and the 
least acceptable lifestyle change was to maintain proper body weight by eating a low 
calorie diet (30,6% of respondents). ConClusions: Adolescents with hypertension 
in varying degrees adhere to a medical recommendations related to the hypertension 
treatment. From the available literature data indicate that the current effective way 
to improve cooperation with the patient’s is education.
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objeCtives: Previous research has shown the impact of chronic heart failure (CHF) 
on health-related quality of life (HRQL). Less is known regarding the impact of 
reduced ejection fraction (HFrEF) on HRQL. The aim of this study was to elicit utility 
values for CHF with HFrEF or preserved ejection fraction (HFpEF) by New York Heart 
Association (NYHA) classification system in the UK. In addition, utility values for 
events such as stroke, myocardial infarction (MI) and chronic kidney disease (CKD) 
were estimated. Methods: Health states were developed from concept elicitation 
interviews with CHF patients (N= 10) and cardiologists (N= 5). Draft health states 
were validated in cognitive debrief interviews with different patients (N= 5) and 
cardiologists (N= 4) and finalised with scientific input from experts. The resulting 
health states (n = 10) were piloted with general public to check understanding. 
General public participants (n= 100) completed background questions and rated each 
state using visual analogue scale and time trade-off (TTO) assessments (with lead 
time method for states worse than dead). Results: The mean TTO utility for HF-rEF 
ranged between 0.86 (SD= 0.19) (NYHA class II); 0.60 (SD= 0.23) (NYHA III) to 0.28 
(SD= 0.41) (NYHA IV). Equivalent values for HF-pEF were 0.83 (SD= 0.24) (NYHA II); 
0.55 (SD= 0.28) (NYHA III) to 0.27 (SD= 0.35) (class IV) respectively. Other values 
were post hospitalisation after stroke (mean= 0.30, SD= 0.43); post MI (mean= 0.45, 
SD= 0.37) and CKD (mean= 0.78, SD= 0.21). Post-hospitalisation states captured a 
period of upto three months after the event. ConClusions: This study shows the 
effect that NYHA class has on HRQL for people with CHF in the UK. The findings 
showed that HFrEF and HFpEF were very similar. Participants considered events such 
as recovery from stroke to have significant impact on HRQL. These are important 
data to consider in evaluating outcomes of treatments and should be reflected in 
cost effectiveness models in CHF where relevant.
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objeCtives: Cost-utility models are frequently conducted to compare treatments 
intended to prevent or delay cardiovascular events. Most published utilities repre-
sent post-event health states without incorporating the disutility of the event or 
reporting the time between the event and utility assessment. Therefore, the objec-
tive of this study was to estimate health state utilities representing cardiovascular 
conditions while distinguishing between acute impact including the cardiovascular 
event and the chronic post-event impact. Methods: Health states were drafted 
and refined based on literature review, clinician interviews, and a pilot study. Three 
cardiovascular conditions were described: stroke, acute coronary syndrome (ACS), 
and heart failure. One-year acute health states represented the event and gradual 
